Sana Biotechnology (SANA)
(Delayed Data from NSDQ)
$4.26 USD
+0.03 (0.71%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.26 0.00 (0.00%) 5:14 PM ET
3-Hold of 5 3
D Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SANA 4.26 +0.03(0.71%)
Will SANA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SANA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SANA
SANA Gears Up to Report Q4 Earnings: What's in the Cards?
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
SANA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
Other News for SANA
SANA: Promising Trial Results for Immunosuppression-Free Diabetic Treatment
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking ...
Sana Biotechnology announces publication on clinical data from transplantation
Commit To Purchase Sana Biotechnology At $2.50, Earn 28% Using Options
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes